live life with confidence and ease -...

2019 RAYMOND JAMES | June 18, 2019

LIVE LIFE WITH CONFIDENCE AND EASE

2019 Raymond James

June 18, 2019

2019 RAYMOND JAMES | June 18, 2019 2

FORWARD-LOOKINGSTATEMENTS

This presentation contains forward-looking statements that are not purely historical regardingSenseonics’ or its management’s intentions, beliefs, expectations and strategies for the future.All forward-looking statements and reasons why results might differ included in this presentationare made as of the date of this presentation, based on information currently available toSenseonics, deal with future events, are subject to various risks and uncertainties, and actualresults could differ materially from those anticipated in those forward-looking statements.The risks and uncertainties that may cause actual results to differ materially from Senseonics’current expectations are more fully described in Senseonics’ annual report on Form 10-K forthe period ended December 31, 2017, as filed with the Securities and Exchange Commission onMarch 13, 2018, its most recent quarterly report on Form 10-Q for the period ended September30, 2018, as filed with the Securities and Exchange Commission on November 8, 2018, and itsother reports, each as filed with the Securities and Exchange Commission. Senseonics assumesno obligation to update any such forward-looking statement after the date of this report or toconform these forward-looking statements to actual results.


HIGH GROWTHMARKET

CGM Fastest Growing Segment*

34% CAGR

$1.2$1.8

$2.8

~$3.9

2019201820172016CGM Global Market Size

$5

$4

$3

$2

$1

Rev

enue

In B

illio

ns (

$)

* Top 4 CGM company estimates based

upon available publicly stated guidance,

historic performance, and external

CGM market models.

~$2.0BU.S. MARKET

0

1

2

3

4

5

6

2017 2018 2019 2020 2021

$2.8

~$3.9

$4.8

$5.7

Rev

enu

e in

Bill

ion

s ($

)

CGM Global Market Size

$1.8

34% CAGR

CGM Fastest Growing Segment*


27% DISCONTINUE CGMUSE WITHIN 1 YEAR

71% 61% 41% 28%CGM NOT WORKINGPROPERLY/ACCURATELY ENOUGH

PROBLEMS WITHADHESIVE/INSERTION

UNCOMFORTABLETO WEAR

CGM TOO BIG

Type 1 Diabetes (T1D) Exchange Registry (2016)

2019 RAYMOND JAMES | June 18, 2019 52019 RAYMOND JAMES| June 18, 2019


36 X A YEAR

PATIENTS HAVE TO SWITCHOUT THEIR SENSOR WITH

OTHER CGM


36 X A YEAR


OTHER CGM

2-4 X A YEAR


EVERSENSE

Labeled up to 90 days (US) and180 days (Europe).


THE EVERSENSE® CGM SYSTEM

SENSOR

+ Fully implanted

+ Small size

+ Up to 180 days

SMART

TRANSMITTER

+ On-body vibe alerts

+ Removable/

rechargeable

+ Gentle adhesive

EVERSENSE APP

+ Real-time readings every 5 mins

+ No extra receiver+ Trends, threshold and

predictive alerts

EVERSENSE NOW

+ Share capability

Labeled up to 90 days (US) and 180 days (Europe).

EVERSENSE CLOUD

FOR INVESTORS ONLY | Guggenhe im MedTech Disruptors Summit 2019


COUNTRIESWE’RE IN

2019 RAYMOND JAMES| June 18, 2019

2018 for

Eversense® CGM

(90-Day System)

2017 for

Eversense® XL CGM

(180-Day System)

2016 for

Eversense® CGM

(90-Day System)


US LAUNCHACCELERATIONAdvances

1

October 2018

Aetna covers approximately22 million lives in the U.S.,adding to the growing bodyof payers processing claimsand paying for Eversense.

AETNAANNOUNCESCOVERAGE OF THEEVERSENSE® CGMSYSTEM



2

November 2018

Making Eversense CGM 90-daytechnology available to morediabetes patients.FDA EXPANDS

EVERSENSE® CGMCERTIFICATION TOINCLUDE NURSEPRACTITIONERS (NP)AND PHYSICIANASSISTANTS (PA)

Giving NPs and PAs anotherCGM option for their patients.

Allowing physicians to bettermanage time and patient flow.



3

February 2019

Now, under most circumstancesand on most MRI machines:

FDA ANNOUNCESEVERSENSEIS NO LONGERCONTRA-INDICATEDFOR MOST MRI’S

The Eversense Smart Sensorneed not be removed beforean MRI - reducing concernsfor patients and doctors alike.

Note: as with all transmitters,the Eversense Smart Transmittermust be removed and storedoutside the procedure room.



4

Approved June 6,2019

FDA APPROVES NON-ADJUNCTIVEINDICATION

Approval expands Eversenseindication as a therapeutic CGMto replace fingerstick blood glucose measurement for dosing decisions.


FIRST LOOK AT U.S. PATIENT DATA


n=205 90-Day Analysis

Mean Sensor Glucose mg/dL 161.8 (33.3)

Mean SD mg/dL 57.4 (14.8)

Mean CV 0.35 (0.06)

Mean GMI% 7.18 (0.8)

% Time spent <54 mg/dL 1.2 (1.7)

% Time spent 54-70 mg/dL 2.9 (2.5)

% Time spent 70-180 mg/dL 62.3 (19.0)

% Time spent 180-250 mg/dL 21.9 (9.7)

% Time spent >250 mg/dL 11.6 (12.8)

*Senseonics Data on File

GLUCOMETRIC DATA ON THE FIRST 205 PATIENTS WHO COMPLETED 90 DAYS FROM SENSOR INSERTION ~1/3 CGM NAÏVE, ~80% T1D

83.7%Percent wear of transmitter (median)

11.2%MARD (27,705 paired points)

~75%Percent of patients who continue with Eversense CGM System


EVERSENSEPATIENTTESTIMONIALS

Personal experience.Individual results may vary.

Dianne M., South Carolina


EVERSENSEPATIENTTESTIMONIALS

Personal experience.Individual results may vary.

Matt C., Colorado


CHANGING REIMBURSEMENTFOR DIABETES


68 MILLION LIVES 2019TARGET 100 MILLION LIVESCoverage

Coding

DME CPTPHARMACY

Payment

INITIAL INSERTION 0446TREMOVAL 0447T

REMOVAL & INSERTION 0448T

HCPPATIENT PATIENT

SENSOR A9276

TRANSMITTER A9277

BRIDGE PROGRAM STRATEGY

1

2

3

4

PATIENT ACCESS TO EVERSENSE FOR $99*

APPEAL MANAGEMENT

PAYER UTILIZATION

ADVOCACY MOBILIZATION

- Single case negotiations

- Drive coverage policy

5 - JDRF, AACE

EVERSENSE ”PIONEERS”

- Rally early adopters

SENSOR K0553

TRANSMITTER K0554


PROGRESS AND KEY INDICATORS

Impact of Eversense Bridge Program

Mix of Patients Switching to Eversense

Installed Base FollowingInitial Product Launch

Metrics are based on average per week prior to Bridge program versus average per week since program launch

Growth

Competitive data based on third-party market data


EUROPE DISTRIBUTORCOMMERCIALIZATION


+167% +266%

>700 >1,000EversenseClinics

TrainedPhysicians

2017 2018 2017 2018

New Patients Sensor Insertions

Roche Diabetes CareSelect EMEA, Asia Pac,

LATAM markets

Rubin MedicalScandinavia distributor

PharmaNovaFinland distributor


EUROPECOMMERCIALEXPERIENCE

10%Traditional CGM

40%FGM

50%New to CGM

NEW PATIENTS(Germany)

Most important

features of the

Eversense System:

• Long sensor life

• Predictive alerts

• Readings on phone

• On-body vibe alerts

• Gentle adhesive


PRODUCTSTRATEGY


Extend

Duration

Interoperability +

Decision Support

Approval for

Pediatrics

Improve

Accuracy

Lower

Cost

Broaden

Target Market

Reduce

Calibration


AUTOMATEDINSULIN DELIVERY

BETA BIONICSPROGRAM

Gen3 iLet™ Bionic

Pancreas System

with Eversense


EVERSENSE PIPELINE

Same sensor technology. Expanded opportunities.

1 2 3

365-DAY

SENSOR LIFE:

AUTONOMOUS

SENSING

ON-DEMAND

TYPE 2

GEMINI

TYPE 1

1x/week calibration

additional analytes

Battery integration FGM long-term wear

w/ no transmitterFGM + CGM

flash when desired,

CGM for peace of mind

2019 RAYMOND JAMES | June 18, 2019

THANK YOU

live life with confidence and ease -...

Documents